Shared decision-making: Definition, Uses, and Clinical Overview

Shared decision-making Introduction (What it is)

Shared decision-making is a structured process where a clinician and patient make healthcare choices together.
It combines clinical evidence with the patient’s goals, values, and preferences.
It is commonly used in cancer screening, diagnosis, and treatment planning.
It can also be used for symptom control, supportive care, and survivorship planning.

Why Shared decision-making used (Purpose / benefits)

Cancer care often involves multiple medically reasonable options that differ in goals, intensity, side effects, time commitment, and impact on daily life. Shared decision-making is used to match the care plan to what matters most to the patient while still reflecting the clinician’s assessment of benefits and risks.

In oncology, the “problem” is not only tumor control. It can include earlier detection, accurate diagnosis, staging (describing how far a cancer has spread), selecting treatment sequences, managing symptoms, and planning follow-up. Many of these decisions involve trade-offs, such as:

• Treating sooner versus observing closely for a period
• Choosing a local treatment (like surgery or radiation) versus a systemic treatment (like chemotherapy, targeted therapy, or immunotherapy)
• Prioritizing cure intent, life prolongation, symptom relief, function preservation, or quality of life
• Accepting more side effects for a higher chance of tumor response, or choosing a gentler approach with a different balance of outcomes

Shared decision-making helps by clarifying what the patient understands, correcting misunderstandings, and making preferences explicit. It also supports informed consent by ensuring the patient is not only told about options, but meaningfully participates in choosing among them.

Potential benefits in cancer care include:

• Better alignment between treatment choices and personal priorities (for example, work, caregiving, mobility, independence, or tolerance for uncertainty)
• Improved understanding of diagnosis, staging, and the purpose of each treatment component
• More realistic expectations about what treatment can and cannot do, which can reduce confusion later
• A clearer plan for managing side effects and for deciding what to do if the cancer responds, remains stable, or progresses
• Support for equitable care by standardizing how options are presented and discussed, especially when choices are preference-sensitive (reasonable people may choose differently)

Indications (When oncology clinicians use it)

Oncology teams commonly use Shared decision-making in scenarios such as:

• Whether to start, defer, or stop screening (when multiple screening strategies are considered reasonable)
• Choosing among biopsy approaches or additional diagnostic tests when more than one pathway is possible
• Discussing staging workup and how results may change treatment options
• Deciding between surgery, radiation therapy, systemic therapy, or combinations/sequences of these treatments
• Selecting between different systemic therapy regimens with different side-effect profiles and visit schedules
• Considering fertility preservation options before treatment that could affect reproductive function
• Weighing reconstruction choices (for example, after cancer surgery) where outcomes and preferences vary
• Deciding on supportive care approaches (pain control, anti-nausea strategies, nutrition support, rehabilitation)
• Considering clinical trial participation versus standard-of-care options
• Making goals-of-care decisions when the cancer is advanced or when treatments are primarily palliative (focused on comfort and function)

Contraindications / when it’s NOT ideal

Shared decision-making is not always the best fit in its full, deliberative form. Situations where it may be limited or where a different approach is needed include:

• Medical emergencies requiring immediate action (for example, uncontrolled bleeding, airway compromise, spinal cord compression), where time for discussion is constrained
• When a patient lacks decision-making capacity and no appropriate surrogate decision-maker is available at that moment
• When a patient clearly states they do not want to participate in decisions and prefers the clinician to recommend a plan (patient preference still matters, but the process may be simplified)
• When there is only one medically appropriate option (for example, a treatment is clearly contraindicated due to severe allergy or organ failure)
• Severe communication barriers that cannot be adequately addressed in the moment (for example, no interpreter available), where proceeding could risk misunderstanding
• Situations with substantial misinformation or coercion from others, where additional support, privacy, or ethics consultation may be needed before decisions are made
• Extreme distress or cognitive overload (for example, immediately after traumatic news), where decisions may need to be staged over time with additional support

How it works (Mechanism / physiology)

Shared decision-making is not a drug or procedure, so it does not have a physiological “mechanism of action” in the usual sense. Instead, it works through a clinical communication pathway that improves how decisions are made in complex care.

At a high level, the pathway includes:

• Defining the decision: clarifying what choice is being made now (and what can be deferred)
• Sharing clinical information: the clinician explains the diagnosis, stage, and medically reasonable options, including expected benefits, uncertainties, and potential harms
• Eliciting patient values and context: the patient shares goals (such as cure, longevity, symptom relief), concerns (such as nausea, neuropathy, fatigue), and life factors (transportation, caregiving, work, finances, faith, prior experiences)
• Deliberation and preference-sensitive trade-offs: the clinician and patient compare options in light of the patient’s priorities
• Making and documenting a plan: the team records the decision, the reasoning, and the next steps, including how the plan will be revisited if circumstances change

Relevant oncology concepts often embedded in this discussion include:

• Tumor biology (how the cancer behaves), which varies by cancer type and stage and may be influenced by grade, receptor status, genetic markers, or other lab findings
• Treatment intent (curative, adjuvant, neoadjuvant, maintenance, or palliative), which shapes what outcomes are realistically targeted
• Organ system considerations (for example, lung, breast, colon, blood/lymph), which influence symptom risks, treatment tolerability, and surveillance approaches

“Onset” and “duration” are not applicable as they would be for a medication. The closest relevant property is reversibility: Shared decision-making is typically iterative and revisitable. Decisions can be adjusted as new imaging, pathology, side effects, or life circumstances emerge.

Shared decision-making Procedure overview (How it’s applied)

Shared decision-making is a care process rather than a single procedure. In oncology, it is often applied repeatedly across the care timeline, with different decisions at each stage.

A common workflow looks like this:

1. Evaluation / exam
   The clinician reviews symptoms, medical history, medications, comorbidities, and performs a focused exam. The patient’s goals and immediate concerns are introduced early.

2. Imaging / biopsy / labs
   Tests are selected to clarify the diagnosis. The team explains what each test is for and what results may mean. Some decisions here involve choosing between different diagnostic approaches.

3. Staging
   The cancer stage is determined using imaging, pathology, and sometimes surgical findings. Staging helps estimate prognosis and informs whether local or systemic therapies are typically considered.

4. Treatment planning
   Options are discussed, often in a multidisciplinary setting (for example, involving medical oncology, surgical oncology, radiation oncology, radiology, pathology, and supportive care). The discussion focuses on benefits, risks, uncertainties, and how each option fits the patient’s priorities.

5. Intervention / therapy
   The chosen plan is started (for example, surgery, radiation, systemic therapy, or a combination). Supportive care plans are commonly layered in to prevent or reduce symptoms and side effects.

6. Response assessment
   The team evaluates how the cancer is responding using symptoms, exam, labs, and imaging when appropriate. If the response is not as expected—or side effects are problematic—options are revisited.

7. Follow-up / survivorship
   The plan transitions to surveillance, rehabilitation, long-term side-effect monitoring, and health maintenance. Decisions may include follow-up intensity, late-effect screening, and return-to-work planning.

Throughout, clinicians may use tools such as decision aids, printed summaries, teach-back (asking patients to restate key points in their own words), and structured documentation of goals and preferences.

Types / variations

Shared decision-making can look different depending on the setting, diagnosis, and the urgency of the decision. Common variations include:

• Screening-focused Shared decision-making
  Used when discussing screening tests (what they can detect, false positives, overdiagnosis, and follow-up testing). The balance of benefits and harms can vary by age, risk factors, and overall health.

• Diagnostic Shared decision-making
  Used when multiple diagnostic paths exist, such as choosing between imaging options, biopsy routes, or sequencing of tests to confirm cancer type and guide treatment.

• Treatment selection Shared decision-making
  Common when there are multiple medically reasonable treatments, such as:

• Local therapy options (surgery and/or radiation)

• Systemic therapy choices (chemotherapy, targeted therapy, immunotherapy, hormone therapy), where eligibility often depends on tumor type and biomarkers

• Combined-modality plans (for example, chemotherapy plus radiation, or surgery followed by systemic therapy), where the sequence may differ

• Supportive care Shared decision-making
  Applied to symptom management and function preservation (pain, fatigue, nausea, appetite changes, neuropathy, anxiety, sleep problems), often involving palliative care teams alongside oncology.

• Survivorship Shared decision-making
  Focused on follow-up schedules, monitoring for recurrence, managing late effects (long-term or delayed side effects), and supporting return to daily activities.

• Adult vs pediatric considerations
  In pediatrics, parents or guardians usually provide consent, and the child’s assent (developmentally appropriate involvement) may be included. Decision-making often accounts for growth, development, schooling, and family dynamics.

• Solid-tumor vs hematologic care
  Blood cancers may involve decisions around transfusions, infection prevention, stem cell transplant evaluation, and long treatment timelines. Solid tumors may emphasize surgical options, radiation fields, and organ-specific function.

• Inpatient vs outpatient settings
  Inpatients may face faster decisions (for example, complications requiring urgent management), while outpatient settings often allow more time for deliberation and second opinions.

Pros and cons

Pros:

• Encourages care choices that reflect a patient’s goals, values, and daily-life realities
• Improves understanding of diagnosis, staging, and what treatment is intended to achieve
• Supports informed consent as an active conversation rather than a signature alone
• Helps anticipate side effects and practical burdens (appointments, transportation, caregiver needs)
• Can reduce decisional regret by clarifying trade-offs before treatment begins
• Creates a documented rationale that supports continuity across multiple clinicians and settings
• Strengthens trust and communication within the care team

Cons:

• Requires time, attention, and good communication skills, which can be harder in busy clinics
• Can feel overwhelming when many options exist or when information is complex
• May be challenging when prognosis is uncertain or when evidence does not clearly favor one approach
• Unequal access to decision aids, interpreters, or multidisciplinary input can limit effectiveness
• Family disagreement or external pressure can complicate the patient’s ability to express preferences
• Emotional distress, fatigue, or cognitive side effects can reduce a patient’s capacity to process information
• Documentation and follow-through can be inconsistent across healthcare systems

Aftercare & longevity

Shared decision-making does not “wear off,” but its impact depends on how well the decisions are revisited as the clinical situation changes. In cancer care, outcomes and durability of a plan commonly depend on factors that vary by cancer type and stage, including tumor biology, response to therapy, and overall health.

Practical factors that can influence how well Shared decision-making holds up over time include:

• Clarity of goals and intent: whether the patient and team share the same understanding (for example, cure-focused versus symptom-focused treatment)
• Quality of follow-up and monitoring: planned reassessments help catch side effects, complications, or changes in tumor status early
• Treatment tolerance and supportive care: symptom control, nutrition support, rehabilitation, and mental health care can affect whether a patient can continue or complete a chosen plan
• Comorbidities and baseline function: heart, lung, kidney, liver, or neurologic conditions can influence treatment feasibility and risk
• Adherence and logistics: the ability to attend visits, obtain medications, and complete imaging/lab monitoring can shape real-world outcomes
• Care coordination: transitions between hospital and clinic, or between specialties, can introduce gaps unless decisions and rationales are clearly communicated
• Survivorship resources: management of late effects, fatigue, pain, sexual health concerns, and return-to-work planning can affect long-term quality of life

Many patients revisit decisions at key milestones, such as after pathology results, after the first assessment scan, when side effects accumulate, or when life circumstances change.

Alternatives / comparisons

Shared decision-making is one approach to choosing cancer care, and it is often discussed alongside other decision models and clinical strategies.

• Shared decision-making vs clinician-directed decisions (paternalistic model)
  In clinician-directed decisions, the clinician chooses the plan with limited patient input. This may be necessary in emergencies, but in preference-sensitive decisions it can leave patients feeling unheard or surprised by trade-offs.

• Shared decision-making vs informed consent alone
  Informed consent can be a one-way disclosure of risks and benefits followed by agreement. Shared decision-making aims for a two-way process: understanding options, clarifying values, and selecting a plan collaboratively.

• Shared decision-making vs decision aids alone
  Decision aids (brochures, videos, questionnaires) can improve understanding, but they are not a substitute for clinician judgment and individualized context. Shared decision-making typically combines tools with conversation.

• Shared decision-making alongside observation or active surveillance
  Observation or active surveillance may be reasonable in selected cancers or precancerous conditions, depending on risk features and patient preference. Shared decision-making helps patients weigh anxiety, follow-up intensity, and the possibility of later treatment.

• Shared decision-making across major treatment modalities
  When comparing surgery, radiation, and systemic therapy, the “right” choice may depend on tumor location, stage, biomarkers, comorbidities, and goals (function preservation, recovery time, side-effect tolerance). Shared decision-making provides a framework to compare these options without assuming a single universally preferred pathway.

• Shared decision-making and clinical trials
  Clinical trials can offer access to new therapies, but they may involve additional visits, testing, and uncertainties. Shared decision-making helps clarify what is known, what is unknown, and what participation would require.

Shared decision-making Common questions (FAQ)

Q: Does Shared decision-making mean the patient makes the decision alone?
No. Shared decision-making is collaborative: clinicians contribute medical expertise and patients contribute preferences and life context. The goal is a plan that is medically reasonable and personally aligned.

Q: Is Shared decision-making required before cancer treatment starts?
Practices vary by clinician and case. Many cancer decisions benefit from it, especially when multiple options are reasonable, but emergencies or clearly indicated treatments can limit how much deliberation is possible.

Q: Will Shared decision-making involve painful tests or procedures?
Shared decision-making itself is a conversation process and is not painful. However, the decisions may involve tests or treatments that can cause discomfort (such as biopsies or infusions). Teams often discuss comfort measures and supportive care options as part of planning.

Q: Will I need anesthesia for decisions made through Shared decision-making?
No anesthesia is needed for the decision-making conversation. Some chosen interventions (for example, surgery or certain biopsies) may involve anesthesia or sedation, depending on the procedure and clinical setting.

Q: How long does Shared decision-making take?
The time varies by decision complexity, the number of options, and how urgently a plan is needed. Some choices can be discussed in one visit, while others unfold over several appointments as test results return.

Q: What does Shared decision-making cost?
Costs vary by healthcare system, insurance coverage, and what tests or treatments are selected. The conversation itself is usually part of clinical care, but downstream costs can differ widely among options (for example, medications, radiation visits, surgery, imaging, and supportive therapies).

Q: Is Shared decision-making safe—can it delay treatment?
It is intended to support timely, informed choices, not unnecessary delay. That said, complex decisions can take time, and clinicians often balance deliberation with the urgency of cancer treatment. When time is critical, teams may narrow options and revisit decisions as soon as feasible.

Q: Can Shared decision-making reduce side effects?
It does not eliminate side effects, because side effects depend on the treatments chosen and individual biology. It can help patients choose among options with different side-effect profiles and prepare a supportive care plan to manage expected symptoms.

Q: Can I work or keep normal activities during Shared decision-making and treatment?
Shared decision-making has no activity restrictions. Activity during treatment varies by therapy type, side effects, job demands, and overall health. Discussions often include practical planning for fatigue, appointment schedules, and safety-sensitive work.

Q: How are fertility and sexual health addressed in Shared decision-making?
Fertility and sexual health can be included as explicit priorities, especially before therapies that may affect reproductive organs or hormone function. Options may include fertility preservation referrals or treatment adjustments when medically appropriate, and the details vary by cancer type and stage.